Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Rare Gastrointestinal Diseases Treatment Market Snapshot (2023 to 2033)

The global rare gastrointestinal diseases treatment market garnered a market value of US$ 1,314.8 million in 2022. The market is set to reach US$ 1,353.2 million in 2023 and is expected to register a CAGR of 3.7% from 2023 to 2033. Following this moderate growth rate, the worldwide adoption of gastrointestinal rare disease treatment could accumulate a market value of US$ 1,940.6 million by 2033.

The growth of the rare gastrointestinal diseases treatment market can be attributed to increasing awareness of gastrointestinal diseases and the development of various medications.

A rare gastrointestinal disease occurs uncommonly in the overall population. According to the International Rare Diseases Research Consortium (IRDiRC), it is a rare disease that affects less than 1 in 2,000 citizens. Gastrointestinal diseases affect fewer than 200,000 patients in the United States. Yet for the combined population of 800 million, this could range from a few hundred to as many as 400,000 individuals for any rare disease. In addition, government initiatives, funding, and collaboration in rare gastrointestinal disease projects are enhancing the treatment available for the market.

Report Attributes or Data Points Details
Global Rare Gastrointestinal Diseases Treatment Market Valuation in 2022 US$ 1,314.8 million
Estimated Global Market Share in 2023 US$ 1,353.2 million
Forecasted Global Market Size by 2033 US$ 1,940.6 million
Projected Global Market Growth Rate from 2023 to 2033 3.7% CAGR
Historical Market Growth Rate from 2018 to 2022 2.9% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Rare Gastrointestinal Diseases Treatment Demand Analysis (2018 to 2022) Vs. Market Outlook (2023 to 2033)

In terms of value, the global demand for gastrointestinal rare disease treatment was a mere US$ 1,139.9 million in 2018. According to a recent report from FMI, during the historical period between 2018 and 2022, sales witnessed significant growth, registering a year-on-year growth rate of 2.9%.

Gastrointestinal rare disease treatment is available to overcome this life-threatening gastrointestinal rare disease that can help to reduce the impact on the worldwide diseased population. New therapies developed and approved by the specific regulatory authority can improve the quality and quantity of life.

Global cooperation and collaboration amongst scientists, researchers, companies, and government authorities create the opportunity to make new therapies for rare disease treatments.

Increasing awareness regarding treatments, along with the development of different methods of medicine, is accelerating the demand for the same. Improving healthcare systems, technology to detect gastrointestinal diseases, and immediate relief positively influences the demand for the gastrointestinal treatment market.

Some Prominent Drivers of the Rare Gastrointestinal Diseases Treatment Market

Rising Prevalence of Gastrointestinal Diseases Increasing Dependency on Treatment

Collectively, around 30 million people are living with a rare disease in the United States and another 3.5 million in the United Kingdom. Around the globe, the rare disease community is estimated to include 350 million people, creating a huge opportunity expected to boost the gastrointestinal rare disease treatment market during the forecast period.

Gastrointestinal diseases related to the small intestine, diarrhea, and irritable bowel syndrome affect populations of different age groups. This has led to most people seeking treatment for these ailments. Moreover, the availability of medication and nutrition treatments supports the growth of the market.

Awareness and Government Initiatives are Driving the Growth of the Rare Gastrointestinal Diseases Market

An increase in government initiative and funding, capital venture funding raised by various investors, and reimbursement policy improvements are the key drivers for the rare gastrointestinal diseases treatment market. Collaboration among physician, researcher, and manufacturers also boost the market growth for gastrointestinal rare disease treatment.

Researchers are studying the growth of bacteria in the intestines along with producing different medicines for the gastrointestinal conditions. This has led to a plethora of options for treatments. Moreover, increasing awareness regarding gastrointestinal diseases amongst people is driving the growth of the rare gastrointestinal diseases treatment market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Challenges Faced by the Rare Gastrointestinal Diseases Treatment Market

Lack of Awareness Restraining Gastrointestinal Rare Disease Treatment Market Growth

Lack of awareness causes a delay in the diagnosis of rare gastrointestinal diseases. In addition, the third-world category of orphan drugs has resulted in scarce commercial interest for private investors. Furthermore, a lack of regulatory framework in emerging countries combined with a lack of skilled healthcare personnel could be a crucial restraint for the rare gastrointestinal diseases treatment market.

Furthermore, each faces unique gastrointestinal disease problems. This has led to treating patients with different methods. Although research is underway for developing treatments, only some treatments can suit one. These factors are affecting the gastrointestinal rare disease treatment market.

Region-wise Insights

Regional Market Comparison Global Market Share in Percentage
North America 39.5%
Europe 28.3%

Prevalence of Gastrointestinal Diseases Increasing Demand for Treatment in North America

Government Initiatives Supporting the Growth of Gastrointestinal Treatments in the Region

North America dominates in the treatment of rare gastrointestinal diseases. It may continue to dominate the global market because of the increase in patients having rare gastrointestinal diseases. This can be attributed to unprecedented changes in lifestyle, resulting in stomach ulcers, bleeding, hemorrhoids, and anemia, among others.

Moreover, the presence of government initiatives aimed at preventing as well as treating gastrointestinal diseases is expected to drive the market.

For instance, the Integrated Global Action Plan for Diarrhea by UNICEF and WHO aims to minimize preventable childhood deaths due to diarrhea by providing interventions and services to raise awareness and provide access to treatment and preventive measures. Thus, North America held more than 39.5% market share for the rare gastrointestinal diseases treatment market in 2022.

Regional Market Comparison Global Market Share in Percentage
United States 34.7%
Germany 7.6%
Japan 3.9%

Commercialization of Medication Fueling Growth of Rare Gastrointestinal Diseases Treatment in Europe

Technological Graduation, along with the Immediate Requirement for Treatment, Drives Market Growth

Europe is anticipated to exhibit exponential growth throughout the forecast period. This is likely to be fueled by consistent efforts undertaken by key players, which include research and development investments as well as commercialization of branded drugs at a relatively lower price.

In addition, the urgent need to curb the high incidence rate of gastrointestinal disorders and the technological gradation of healthcare infrastructure are predicted to present the regional market with high potential growth opportunities over the forecast period. Thus, Europe possessed almost 28.3% of the global market share for the rare gastrointestinal diseases treatment market in 2022.

Regional Markets CAGR (2023 to 2033)
United Kingdom 2.8%
China 4.9%
India 4%
Australia 3.6%

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Tech-Savvy Hospitals Offering Adequate Services to Patients Suffering from Rare Gastrointestinal Diseases Treatment

Technologically Advanced Equipment Attracting Patients to Hospitals

Development of the healthcare sector by technology and innovation is boosting the demand for the rare gastrointestinal disease treatment market. Moreover, technologically advanced machines for diagnosing various components related to gastrointestinal issues are offering solutions at the earliest.

In addition, the rapid adoption of undertaking tests by patients and hospitals possessing the adequate equipment to carry tests is accelerating the growth of hospitals in the market. Thus, by the end user, hospitals possessed nearly 41.4% of the global market share for the rare gastrointestinal diseases treatment market in 2022.

Category By Treatment
Top Segment Medication
Market Share in Percentage 54.2%
Category By End User
Top Segment Hospitals
Market Share in Percentage 41.4%

Important Considerations to Explain Why the Medication Segment Performs Better than the Nutritional Support Segment

Drug Discovery, Targeted Medicines, and Creative Treatment Methods Have all Advanced Significantly in the Pharmaceutical Industry

Pharmaceutical firms are investing in research and development to provide medicines targeting the underlying causes of rare gastrointestinal illnesses. It is gaining a lot of interest from healthcare professionals since they frequently aim to relieve symptoms and delay the course of the disease.

A sizable pool of patients with rare gastrointestinal diseases was generated due to the rise in diagnoses in the last few years. Medications target certain biological pathways and illness processes to treat each patient more effectively and personally. Thus, the possibility for better results and fewer adverse effects has made the medication approach more popular than nutritional methods.

Start-ups for the Rare Gastrointestinal Diseases Treatment Market

Key start-up players in the rare gastrointestinal diseases treatment market are Synergy Pharmaceuticals, Ventyx Biosciences, Metacrine, Capso Vision, and Ritter Pharmaceuticals.

  • Ventyx Biosciences, a key player in autoimmune and inflammatory disorders, is focusing on developing various medicines for inflammatory bowel diseases for people of all age groups.
  • Metacrine, a key player in the gastrointestinal liver diseases, is focusing on designing customized therapies for patients suffering from gastrointestinal problems.

Market Competition

Key players in the market include Bayer Pharmaceutical Corp, Teva Pharmaceutical, Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline PLC, Eli Lilly and CO., Johnson & Johnson, and others.

  • In January 2021, GlaxoSmithKline PLC presented positive efficacy data of dostarlimb in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium. Through this, the company focuses on studying the effects of rare gastrointestinal diseases and providing treatments for them.
  • In May 2022, Eli Lilly and Co launched a CONFIDE Study to understand the burden of inflammatory bowel diseases and how it affects patients. The company has launched the CONFIDE portal to understand how gastrointestinal diseases affect patients mentally and physically. In addition, the company plans to offer customized treatments to patients.

Report Scope

Report Attribute Details
Market Value in 2022 US$ 1,314.8 million
Market Value in 2033 US$ 1,940.6 million
Growth Rate CAGR of 3.7% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Treatment Type
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • The Middle East and Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Argentina
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa
Key Companies Profiled
  • Bayer Pharmaceutical Corp
  • Teva Pharmaceutical
  • Novartis AG
  • Sanofi
  • Pfizer, Inc.
  • GlaxoSmithKline PLC
  • Eli Lilly and CO.
  • Johnson & Johnson
Customization Available Upon Request

Key Segments Profiled in the Industry

By Treatment Type:

  • Medications
  • Nutritional Support

By End User:

  • Hospitals
  • Research Institutes
  • Other End User Settings

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa (MEA)

Frequently Asked Questions

How much will the market be worth in 2023?

A market value of US$ 1,353.2 million is expected in 2023.

What was the projected market share in North America?

The CAGR for North America between 2018 and 2022 was 39.5%.

What is the expected market size in 2033?

By 2033, the market is expected to reach US$ 1,940.6 million.

Which treatment type is expected to dominate the market?

Medications will account for 54.2% of the market in 2023.

What will the China market look like in 2033?

Growth in China is steady at 4.9% between 2023 and 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Rare Gastrointestinal Diseases Treatment

        5.3.2. Rare Gastrointestinal Diseases Treatment

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Rare Gastrointestinal Diseases Treatment

        6.3.2. in Research Institutes

        6.3.3. in Other End User Settings

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Treatment Type

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment Type

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment Type

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Type

        9.3.3. By End User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Treatment Type

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By End User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Treatment Type

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By End User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Treatment Type

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Treatment Type

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Treatment Type

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment Type

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Treatment Type

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Treatment Type

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Treatment Type

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Treatment Type

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Treatment Type

            15.5.2.2. By End User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Treatment Type

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Treatment Type

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Treatment Type

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Treatment Type

            15.9.2.2. By End User

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Treatment Type

            15.10.2.2. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Treatment Type

            15.11.2.2. By End User

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Treatment Type

            15.12.2.2. By End User

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Treatment Type

            15.13.2.2. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Treatment Type

            15.14.2.2. By End User

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Treatment Type

            15.15.2.2. By End User

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Treatment Type

            15.16.2.2. By End User

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Treatment Type

            15.17.2.2. By End User

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Treatment Type

            15.18.2.2. By End User

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Treatment Type

            15.19.2.2. By End User

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Treatment Type

            15.20.2.2. By End User

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Treatment Type

            15.21.2.2. By End User

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Treatment Type

            15.22.2.2. By End User

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Treatment Type

            15.23.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Treatment Type

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Bayer Pharmaceutical Corp

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Teva pharmaceutical

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Novartis AG

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Sanofi

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Pfizer, Inc.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. GlaxoSmithKline PLC

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Eli Lilly and CO.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Johnson & Johnson

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. F. Hoffmann-La Roche Ltd.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. AstraZeneca.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 12: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 15: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 24: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 14: Global Market Attractiveness by End User, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 29: North America Market Attractiveness by End User, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Western Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 47: Western Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 55: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 56: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 58: Western Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 59: Western Europe Market Attractiveness by End User, 2023 to 2033

Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Eastern Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 62: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 70: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 73: Eastern Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 74: Eastern Europe Market Attractiveness by End User, 2023 to 2033

Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 76: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 77: South Asia and Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 88: South Asia and Pacific Market Attractiveness by Treatment Type, 2023 to 2033

Figure 89: South Asia and Pacific Market Attractiveness by End User, 2023 to 2033

Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 91: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 92: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 98: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 100: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 101: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 102: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 103: East Asia Market Attractiveness by Treatment Type, 2023 to 2033

Figure 104: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 106: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 107: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033

Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 118: Middle East and Africa Market Attractiveness by Treatment Type, 2023 to 2033

Figure 119: Middle East and Africa Market Attractiveness by End User, 2023 to 2033

Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Rare Disease Clinical Trials Market

Published : March 2023

Healthcare

Gastrointestinal Stent Market

Published : February 2023

Explore Healthcare Insights

View Reports

Rare Gastrointestinal Diseases Treatment Market